This company has been acquired
Agile Therapeutics Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Agile Therapeutics.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth | 23.7% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
Recent updates
Agile appoints chief commercial officer from within ranks amid leadership revamp
Oct 10Agile gains as H.C. Wainwright sees 630% upside potential
Jul 11Agile Therapeutics prices $24M upsized stock offering
Jul 01Agile Therapeutics: Twirla's Lackluster Launch Forces Me To Change My Strategy
Apr 04Agile Therapeutics: Bullish On Capitulation And Max Pain
Oct 19Agile Therapeutics: Another Quarter Of Progress And Another Opportunity To Buy
Jul 30Agile Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 06How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Did Insiders Buy, In The Last Year?
Feb 25Agile Therapeutics issues cash projection at JP Morgan healthcare conference
Jan 14Assessing Agile Therapeutics
Jan 10How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Do Institutions Own?
Jan 04Agile Therapeutics announces peer-reviewed publication of late-stage study for Twirla contraception patch
Nov 30Agile Therapeutics EPS in-line
Nov 12In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Agile Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2024 | 22 | -16 | -2 | -2 | N/A |
3/31/2024 | 21 | -8 | -10 | -10 | N/A |
12/31/2023 | 20 | -14 | -10 | -10 | N/A |
9/30/2023 | 20 | -14 | -11 | -11 | N/A |
6/30/2023 | 16 | -19 | -28 | -28 | N/A |
3/31/2023 | 13 | -20 | -23 | -23 | N/A |
12/31/2022 | 11 | -25 | -36 | -36 | N/A |
9/30/2022 | 8 | -41 | -51 | -51 | N/A |
6/30/2022 | 7 | -52 | -53 | -53 | N/A |
3/31/2022 | 6 | -64 | -66 | -65 | N/A |
12/31/2021 | 4 | -71 | -65 | -65 | N/A |
9/30/2021 | 3 | -69 | -66 | -66 | N/A |
6/30/2021 | 2 | -68 | -63 | -63 | N/A |
3/31/2021 | 1 | -61 | -54 | -54 | N/A |
12/31/2020 | 1 | -52 | -48 | -47 | N/A |
9/30/2020 | N/A | -40 | -34 | -33 | N/A |
6/30/2020 | N/A | -29 | -23 | -23 | N/A |
3/31/2020 | N/A | -22 | -19 | -19 | N/A |
12/31/2019 | N/A | -19 | -16 | -16 | N/A |
9/30/2019 | N/A | -16 | -16 | -16 | N/A |
6/30/2019 | N/A | -16 | -14 | -14 | N/A |
3/31/2019 | N/A | -18 | -16 | -16 | N/A |
12/31/2018 | N/A | -20 | -17 | -17 | N/A |
9/30/2018 | N/A | -22 | -20 | -20 | N/A |
6/30/2018 | N/A | -26 | -24 | -23 | N/A |
3/31/2018 | N/A | -28 | N/A | -24 | N/A |
12/31/2017 | N/A | -28 | N/A | -25 | N/A |
9/30/2017 | N/A | -27 | N/A | -22 | N/A |
6/30/2017 | N/A | -28 | N/A | -22 | N/A |
3/31/2017 | N/A | -29 | N/A | -23 | N/A |
12/31/2016 | N/A | -29 | N/A | -23 | N/A |
9/30/2016 | N/A | -27 | N/A | -25 | N/A |
6/30/2016 | N/A | -29 | N/A | -25 | N/A |
3/31/2016 | N/A | -29 | N/A | -27 | N/A |
12/31/2015 | N/A | -30 | N/A | -25 | N/A |
9/30/2015 | N/A | -33 | N/A | -26 | N/A |
6/30/2015 | N/A | -30 | N/A | -26 | N/A |
3/31/2015 | N/A | -25 | N/A | -21 | N/A |
12/31/2014 | N/A | -16 | N/A | -15 | N/A |
9/30/2014 | N/A | -12 | N/A | -11 | N/A |
6/30/2014 | N/A | -9 | N/A | -7 | N/A |
3/31/2014 | N/A | -10 | N/A | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if AGRX's forecast earnings growth is above the savings rate (2.5%).
Earnings vs Market: Insufficient data to determine if AGRX's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if AGRX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if AGRX's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if AGRX's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AGRX's Return on Equity is forecast to be high in 3 years time